ketanserin
Enable an agent to identify ketanserin, assess a particular material's fitness for a proposed use, and interpret its pharmacological evidence without conflating chemical identity, receptor effects, and product authorization.
Bundle → Layer → Finding → Questions Filled
6 bundles · 11 layers · 17 findings · 27 questions
Ketanserin identity and forms Establish the parent entity and preserve meaningful distinctions among materials bearing its name.
Parent structure
Recognize ketanserin by chemical structure and corroborating identifiers.
Structure-backed recognition
Require agreement between the claimed ketanserin identity, authoritative structure records, and available sample evidence.
- Which structure record defines the parent ketanserin entity represented by vr.tr.ketanserin? definition
- Which analytical observations support assigning this sample to that structure? measurement
Salt and label boundaries
Relate supplied forms and derivatives to ketanserin without erasing their composition.
Material form accounting
Record counterions, stoichiometry, solvent or water content, and any isotope substitution before transferring parent properties.
- Does this material contain neutral ketanserin, a specified ketanserin salt, or an isotopically labelled derivative? boundary
- What composition evidence supports conversion from weighed material to moles of ketanserin? measurement
Ketanserin batch quality Determine what a particular ketanserin lot contains and whether its evidence supports the intended use.
Analytical confirmation
Connect the lot to direct identity and content measurements.
Identity and content evidence
Separate confirmation of ketanserin identity from quantification of ketanserin content.
- Which reference standard and analytical methods establish this lot's ketanserin identity? provenance
- Is the reported purity a mass assay or chromatographic area percentage, and what uncertainty accompanies it? measurement
Impurities and release
Assess contaminants and the evidence needed to accept a lot for a particular purpose.
Use-specific lot fitness
Judge impurity and residual-solvent results against explicit requirements for the proposed ketanserin application.
- Which related substances, residual solvents, or unassigned peaks are present, and at what measured levels? measurement
- Do the lot's measured attributes satisfy the acceptance criteria for the proposed receptor assay or other use? action
Ketanserin physical state and solutions Track properties and changes that determine how much ketanserin remains in a usable material state.
Form-dependent properties
Attach physical measurements to the actual chemical and solid form.
Qualified physical constants
Require material identity and experimental conditions for thermal, solubility, and ionization measurements.
- Which ketanserin form and method underlie each reported melting interval, decomposition observation, or solubility value? provenance
- What measured pH, temperature, solvent composition, and equilibration time apply to the solubility result? measurement
Solution and storage condition
Assess prepared ketanserin solutions and stored material at the point of use.
Available concentration and stability
Distinguish nominal preparation from verified dissolved concentration and retained chemical integrity.
- After dilution into the final assay medium, what evidence establishes dissolved ketanserin concentration and absence of precipitation? measurement
- Which stability data support use after the recorded storage duration, temperature, light exposure, and freeze-thaw history? action
Ketanserin pharmacological interpretation Represent target interactions and the limits of conclusions drawn from ketanserin experiments.
Target-resolved evidence
Keep each binding or functional result attached to a defined receptor and experimental system.
Binding versus functional blockade
Record affinity and functional antagonist evidence separately, with explicit receptor subtype and species.
- Which evidence establishes ketanserin activity at 5-HT2A and comparison targets in the species being studied? provenance
- Does the reported value measure binding affinity, displacement, or functional antagonism, and under which assay conditions? measurement
Mechanistic specificity
Determine how strongly a ketanserin-sensitive response supports a proposed mechanism.
Competing target explanations
Treat receptor specificity as a conclusion requiring concentration-matched evidence and controls.
- At the tested ketanserin concentration, could alpha-adrenergic or other target activity explain the observed effect? boundary
- Which orthogonal antagonist, genetic control, or direct target measurement would distinguish the proposed receptor mechanism? action
Ketanserin handling and use status Connect handling decisions and proposed uses to evidence for the exact material and jurisdiction.
Material hazard evidence
Identify applicable hazard information for ketanserin in its supplied form and concentration.
Form-specific handling basis
Record the SDS source, revision, jurisdiction, classification, and handling instructions without substituting a different salt or formulation.
- Which current SDS matches this ketanserin material, and what GHS classification and exposure-limit evidence does it provide? provenance
- What containment, protective equipment, storage, and waste route follow from that evidence and the planned operation? action
Research and medicinal boundary
Separate substance properties from permission to use a particular product for a particular purpose.
Dated use authorization
Attach authorization claims to a named product, jurisdiction, route, indication, and verification date.
- Is the proposed use analytical research, an authorized investigation, or use of a licensed medicinal product? boundary
- Which authoritative record establishes the applicable authorization and restrictions on the date of the proposed use? provenance
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these check these first hold for the sense of ketanserin this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these kinds and varieties hold for the sense of ketanserin this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these identifiers and schemes hold for the sense of ketanserin this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these real-world use hold for the sense of ketanserin this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these typical measurements hold for the sense of ketanserin this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these failure modes and hazards hold for the sense of ketanserin this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of ketanserin this model covers, and on what evidence? provenance
Classifiers Filled
- Family
- Thing Registry
- Category
- Physical world and living systems
- Entry kind
- thing
- Plane
- PHY
- Domain
- PHY.MAT
What it is Filled
Ketanserin is a synthetic quinazoline-derived drug that antagonizes serotonin 5-HT2A receptors and also blocks alpha-1 adrenergic receptors, contributing to its blood-pressure-lowering effects.
In scope
- Parent ketanserin identity and verified chemical identifiers
- Relationships to protonated forms, salts, and isotopically labelled ketanserin
- Batch composition, purity, analytical identity, and degradation
- Physical properties, dissolution, and storage under specified conditions
- Receptor interactions and the experimental limits of pharmacological interpretation
- Material-specific hazards and jurisdiction-specific use constraints
Out of scope
- Finished medicinal products, their excipients, and manufacturing specifications
- Patient-specific prescribing, dosing, and treatment decisions
- Complete models of serotonin receptors, adrenergic receptors, or cardiovascular disease
- Chemical synthesis routes and manufacturing plant operations
- Full experimental protocols and laboratory equipment models
Why it exists Filled
Enable an agent to identify ketanserin, assess a particular material's fitness for a proposed use, and interpret its pharmacological evidence without conflating chemical identity, receptor effects, and product authorization.
Distinguishing features Filled
- Confirm the quinazoline-2,4-dione structure bearing a 2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl substituent; a similar name or serotonergic effect does not establish identity. [ChEBI](https://www.ebi.ac.uk/chebi/CHEBI%3A6123)
- Match the parent compound to CAS 74050-98-9, PubChem CID 3822, and formula C22H22FN3O3, then corroborate the actual sample analytically. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Ketanserin)
- Distinguish ketanserin tartrate from the parent compound through counterion composition and material identifiers; PubChem records the tartrate separately as CID 16219944. [PubChem: ketanserin tartrate](https://pubchem.ncbi.nlm.nih.gov/compound/Ketanserin-tartrate)
- Check both serotonergic and alpha-adrenergic activity when interpreting an experimental response; ketanserin's activity does not by itself establish a serotonin-specific mechanism. [ChEBI](https://www.ebi.ac.uk/chebi/CHEBI%3A6123)
What robots and AI may and may not do Filled
Must not
- Recommend, dose or supply it to a person without a prescriber's decision.
- Advise combining it with drugs that prolong the QT interval.
- Present research findings as approved clinical uses.
Only with a human decision
- Any decision to start, stop or change treatment.
May
- Describe ketanserin's receptor actions and its use as a blood pressure drug and research tool.
- Note that it is licensed in only some countries.
Moral aspects Filled
- Patients need honest information about which uses are proven and which are experimental.
Who is affected
- Patients
- Prescribers
- Research volunteers
Owners Filled
Steward
The marketing authorisation holder where it is licensed; the prescriber answers for each use.
Master systems
- National medicines registers
Links to other meta-models Filled
parent
- Q11173 - registry parent class
What else AI and robots need to interact with it Filled
Identity and identifiers required Filled
- Vercy registry: vr.tr.ketanserin
- Wikidata: Q415997 (https://www.wikidata.org/wiki/Q415997)
Direct properties required Filled
- Parent molecular identity: C22H22FN3O3; CAS 74050-98-9; PubChem CID 3822
- Parent molar mass: 395.4 g/mol
- Chemical form: Neutral parent; protonated species; specified salt; specified solvate or hydrate; unresolved
- Identity evidence: Sample linked to reference standard, chromatogram, mass spectrum, and/or NMR assignment
- Assay and impurity profile: Mass fraction %; chromatographic area % recorded separately; named impurities and method
- Dissolved ketanserin concentration: mol/L or mg/mL; parent-equivalent basis; solvent, pH, temperature, and measurement time
- Thermal behavior: Melting interval and decomposition onset in °C with method; boiling point only if experimentally established with pressure
- Target-dependent pharmacological activity: Ki, Kd, IC50, or functional antagonist parameter, with units, target subtype, species, and assay
- Material condition: Verified usable; precipitated; degraded; expired; unverified
- Handling and use evidence: Applicable SDS, hazard classification, exposure-limit evidence, and dated jurisdiction-specific authorization record
Recognition required Filled
- Identity cannot be settled by sight; preparations must be confirmed by label and pharmacy records.
Capabilities and actions required Filled
- Resolve a ketanserin name or identifier to the parent entity and identify the supplied chemical form.
- Calculate parent-equivalent amounts from verified salt stoichiometry, water content, and assay.
- Assess whether a batch or prepared solution meets a specified analytical or experimental requirement.
- Compare receptor evidence while retaining species, assay conditions, and competing target explanations.
- Identify the material-specific handling evidence and product authorization needed for a proposed use.
Hazards and failure modes required Filled
- Can prolong the QT interval and cause dangerous heart rhythms, especially with low potassium.
- Lowers blood pressure and can cause dizziness or fainting.
Standards and interfaces required Filled
- The Anatomical Therapeutic Chemical classification maintained by the WHO Collaborating Centre for Drug Statistics Methodology assigns ketanserin code C02KD01 among serotonin antagonists used as antihypertensives.
Context of use required Filled
- Ketanserin is encountered in pharmacological research investigating serotonin receptors and vascular responses.
- It also appears in antihypertensive treatment literature and medicinal product records, where receptor activity must be distinguished from authorization for a particular use.
Sources Filled
- Wikidata item Q415997: ketanserin - identity and sense of the item
- Wikipedia: Ketanserin - general description of the item
Open questions
- Which verified EC identifier and jurisdiction-specific GHS classifications apply to parent ketanserin and the actual supplied form, and are any authoritative occupational exposure limits established?
- Which experimentally supported melting, decomposition, pKa, solubility, and storage-stability values can be assigned to each relevant ketanserin form without transferring supplier-specific claims?
- What concentration-dependent selectivity evidence distinguishes 5-HT2A antagonism from alpha-adrenergic and other target effects in the intended species and assay?
- Which impurity identities and acceptance limits are justified for the intended ketanserin application, and which unresolved peaks require further characterization?
- What current product authorizations and clinical safety evidence, including cardiac electrophysiology and interaction findings, govern the intended jurisdiction, route, and use?
Machine files
Provenance
thing registry research (pass 2) · unreviewed
Built from: models/things/publications/thing-q415997/spec.json